Colorectal cancer(CRC) has become the third most common cancer in the world. Screening has been shown to be an effective way to identify early CRC and precancerous lesions, and to reduce its morbidity and mortality. S...Colorectal cancer(CRC) has become the third most common cancer in the world. Screening has been shown to be an effective way to identify early CRC and precancerous lesions, and to reduce its morbidity and mortality. Several types of noninvasive tests have been developed for CRC screening, including the fecal occult blood test(FOBT), the fecal immunochemical test(FIT), the fecal-based DNA test and the bloodbased DNA test(the SEPT9 assay). FIT has replaced FOBT and become the major screening test due to high sensitivity, specificity and low costs. The fecal DNA test exhibited higher sensitivity than FIT but its current cost is high for a screening assay. The SEPT9 assay showed good compliance while its performance in screening needs further improvements. These tests exhibited distinct sensitivity and specificity in screening for CRC and adenoma. This article will focus on the performance of the current noninvasive in vitro diagnostic tests that have been used for CRC screening. The merits and drawbacks for these screening methods will also be compared regarding the techniques, usage and costs. We hope this review can provide suggestions for both the public and clinicians in choosing the appropriate method for CRC screening.展开更多
Castleman's disease is a slowly progressive and rare lymphoproliferative disorder.Here,we report a 55-year-old woman with superior mediastinal Castleman's disease being misdiagnosed for a long term.We found a ...Castleman's disease is a slowly progressive and rare lymphoproliferative disorder.Here,we report a 55-year-old woman with superior mediastinal Castleman's disease being misdiagnosed for a long term.We found a 4.3 cm mass localized in the superior mediastinum accompanied with severe clinical symptoms.The patient underwent an exploratory laparotomy,but the mass failed to be totally excised.Pathologic examination revealed a mediastinal mass of Castleman's disease.After radiotherapy of 30 Gy by 15 fractions,the patient no longer presented previous symptoms.At 3 months after radiotherapy of 60 Gy by 30 fractions,Computed tomography of the chest showed significantly smaller mass,indicating partial remission.Upon a 10-month follow-up,the patient was alive and free of symptoms.展开更多
AIM： To evaluate the therapeutic efficiency of replicative adenovirus CNHK300 targeted in telomerase-positive hepatoceUular carcinoma.METHODS： CNHK300, ONYX-015 （55 kDa protein deleted adenovirus） and wtAd5 （wild...AIM： To evaluate the therapeutic efficiency of replicative adenovirus CNHK300 targeted in telomerase-positive hepatoceUular carcinoma.METHODS： CNHK300, ONYX-015 （55 kDa protein deleted adenovirus） and wtAd5 （wild type adenovirus 5） were compared, and virus proliferation assay, cell viability assay, Western blot and fluorescence microscopy were used to evaluate the proliferation and cytolysis selectivity of CNHK300.RESULTS： The replicative multiples in Hep3B and HepG Ⅰ after 48 Ⅱ of CNHK300 proliferation were 40625 and 65326 fold, respectively, similar to that of wtAd5.. However, CNHK300 exhibited attenuated replicative ability in normal fibroblast cell line BJ. CNHK300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection （MOI）, but could not affect growth of normal cells even at a high MOI.CONCLUSION： CNHK300 is a cancer-selective replication-competent adenovirus which can cause oncolysis of liver cancer cells as well as wtAd5 （wild type adenovirus 5）, but had severely attenuated replicative and cytolytic ability in normal cells. This novel strategy of cancer treatment offers a promising treatment platform.展开更多
基金Supported by The Beijing Municipal Science and Technology Project(capital public health project)No.Z151100003915092sponsored by the Beijing Municipal Science and Technology Commission
文摘Colorectal cancer(CRC) has become the third most common cancer in the world. Screening has been shown to be an effective way to identify early CRC and precancerous lesions, and to reduce its morbidity and mortality. Several types of noninvasive tests have been developed for CRC screening, including the fecal occult blood test(FOBT), the fecal immunochemical test(FIT), the fecal-based DNA test and the bloodbased DNA test(the SEPT9 assay). FIT has replaced FOBT and become the major screening test due to high sensitivity, specificity and low costs. The fecal DNA test exhibited higher sensitivity than FIT but its current cost is high for a screening assay. The SEPT9 assay showed good compliance while its performance in screening needs further improvements. These tests exhibited distinct sensitivity and specificity in screening for CRC and adenoma. This article will focus on the performance of the current noninvasive in vitro diagnostic tests that have been used for CRC screening. The merits and drawbacks for these screening methods will also be compared regarding the techniques, usage and costs. We hope this review can provide suggestions for both the public and clinicians in choosing the appropriate method for CRC screening.
文摘Castleman's disease is a slowly progressive and rare lymphoproliferative disorder.Here,we report a 55-year-old woman with superior mediastinal Castleman's disease being misdiagnosed for a long term.We found a 4.3 cm mass localized in the superior mediastinum accompanied with severe clinical symptoms.The patient underwent an exploratory laparotomy,but the mass failed to be totally excised.Pathologic examination revealed a mediastinal mass of Castleman's disease.After radiotherapy of 30 Gy by 15 fractions,the patient no longer presented previous symptoms.At 3 months after radiotherapy of 60 Gy by 30 fractions,Computed tomography of the chest showed significantly smaller mass,indicating partial remission.Upon a 10-month follow-up,the patient was alive and free of symptoms.
基金International Cooperative Key Project of the National Natural Science Foundation of China, No. 30120160824the State 863 High Technology R&D Project of China, No. 2001AA217031
文摘AIM： To evaluate the therapeutic efficiency of replicative adenovirus CNHK300 targeted in telomerase-positive hepatoceUular carcinoma.METHODS： CNHK300, ONYX-015 （55 kDa protein deleted adenovirus） and wtAd5 （wild type adenovirus 5） were compared, and virus proliferation assay, cell viability assay, Western blot and fluorescence microscopy were used to evaluate the proliferation and cytolysis selectivity of CNHK300.RESULTS： The replicative multiples in Hep3B and HepG Ⅰ after 48 Ⅱ of CNHK300 proliferation were 40625 and 65326 fold, respectively, similar to that of wtAd5.. However, CNHK300 exhibited attenuated replicative ability in normal fibroblast cell line BJ. CNHK300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection （MOI）, but could not affect growth of normal cells even at a high MOI.CONCLUSION： CNHK300 is a cancer-selective replication-competent adenovirus which can cause oncolysis of liver cancer cells as well as wtAd5 （wild type adenovirus 5）, but had severely attenuated replicative and cytolytic ability in normal cells. This novel strategy of cancer treatment offers a promising treatment platform.
